FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984139356> ?p ?o ?g. }

• W1984139356 abstract "Three-drug regimens containing gemcitabine, an anthracycline, and a taxane produce response rates of 70%-90% in patients with metastatic breast cancer (MBC) although accompanied by considerable hematologic toxicity. We explored the combination of gemcitabine/epirubicin/docetaxel as neoadjuvant therapy. Docetaxel was administered weekly to decrease myelosuppression.A total of 110 patients with locally advanced or inflammatory breast cancer received neoadjuvant gemcitabine 800 mg/m2 intravenously (I.V.) days 1 and 8, epirubicin 75 mg/m2 I.V. day 1, and docetaxel 30 mg/m2 I.V. days 1 and 8, repeated every 21 days for 4 cycles. Then patients had either mastectomy or breast conservation surgery, and pathologic treatment responses were assessed. After surgery, 4 cycles of adjuvant gemcitabine 1000 mg/m2 I.V. days 1 and 8 and docetaxel 35 mg/m2 I.V. days 1 and 8 were administered at 21-day intervals. After patients completed chemotherapy, locoregional radiation therapy and/or anti-estrogen therapy was administered per standard guidelines.Treatment with 4 cycles of neoadjuvant gemcitabine, epirubicin, and weekly docetaxel resulted in an objective response in 79 of 110 patients enrolled (72%; 95% CI, 63-80%). Twenty of 103 patients (19%) who had surgery had pathologic complete response (pCR). Moderate hematologic toxicity was evident during neoadjuvant therapy, with grade 3/4 neutropenia in 41% and febrile neutropenia in 11% of the patients. Protocol-specified dose modifications were required in 35% of the patients, and 58% of the patients used myeloid growth factors.The pCR rate of 19% achieved with gemcitabine, epirubicin, and weekly docetaxel confirms previous reports with similar 3-drug regimens. The use of a weekly schedule of docetaxel did not appear to reduce the incidence of grade 3/4 hematologic toxicity." @default.
• W1984139356 created "2016-06-24" @default.
• W1984139356 creator A5013755091 @default.
• W1984139356 creator A5022422153 @default.
• W1984139356 creator A5027426024 @default.
• W1984139356 creator A5035397794 @default.
• W1984139356 creator A5053655884 @default.
• W1984139356 creator A5055732582 @default.
• W1984139356 creator A5057798874 @default.
• W1984139356 creator A5065917441 @default.
• W1984139356 creator A5076209303 @default.
• W1984139356 creator A5089747620 @default.
• W1984139356 date "2010-06-01" @default.
• W1984139356 modified "2023-09-27" @default.
• W1984139356 title "A Phase II Trial of Neoadjuvant Gemcitabine, Epirubicin, and Docetaxel as Primary Treatment of Patients With Locally Advanced or Inflammatory Breast Cancer" @default.
• W1984139356 cites W1760955494 @default.
• W1984139356 cites W1777215171 @default.
• W1984139356 cites W18214132 @default.
• W1984139356 cites W1914910183 @default.
• W1984139356 cites W1949597673 @default.
• W1984139356 cites W1970588291 @default.
• W1984139356 cites W1979300931 @default.
• W1984139356 cites W1981522927 @default.
• W1984139356 cites W1985807450 @default.
• W1984139356 cites W2004505747 @default.
• W1984139356 cites W2016596316 @default.
• W1984139356 cites W2018669222 @default.
• W1984139356 cites W2030917851 @default.
• W1984139356 cites W2036294336 @default.
• W1984139356 cites W2037410466 @default.
• W1984139356 cites W2080381918 @default.
• W1984139356 cites W2085185581 @default.
• W1984139356 cites W2118804515 @default.
• W1984139356 cites W2124241126 @default.
• W1984139356 cites W2132926694 @default.
• W1984139356 cites W2133225159 @default.
• W1984139356 cites W2133585870 @default.
• W1984139356 cites W2138021040 @default.
• W1984139356 cites W2138734774 @default.
• W1984139356 cites W2139510434 @default.
• W1984139356 cites W2140654333 @default.
• W1984139356 cites W2148103659 @default.
• W1984139356 cites W2151631271 @default.
• W1984139356 cites W2153158488 @default.
• W1984139356 cites W2159829953 @default.
• W1984139356 cites W2162760540 @default.
• W1984139356 cites W2171958606 @default.
• W1984139356 cites W2262955759 @default.
• W1984139356 cites W2416214373 @default.
• W1984139356 cites W2941436122 @default.
• W1984139356 cites W595222110 @default.
• W1984139356 cites W205190196 @default.
• W1984139356 doi "https://doi.org/10.3816/cbc.2010.n.029" @default.
• W1984139356 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20497920" @default.
• W1984139356 hasPublicationYear "2010" @default.
• W1984139356 type Work @default.
• W1984139356 sameAs 1984139356 @default.
• W1984139356 citedByCount "10" @default.
• W1984139356 countsByYear W19841393562012 @default.
• W1984139356 countsByYear W19841393562013 @default.
• W1984139356 countsByYear W19841393562014 @default.
• W1984139356 countsByYear W19841393562017 @default.
• W1984139356 crossrefType "journal-article" @default.
• W1984139356 hasAuthorship W1984139356A5013755091 @default.
• W1984139356 hasAuthorship W1984139356A5022422153 @default.
• W1984139356 hasAuthorship W1984139356A5027426024 @default.
• W1984139356 hasAuthorship W1984139356A5035397794 @default.
• W1984139356 hasAuthorship W1984139356A5053655884 @default.
• W1984139356 hasAuthorship W1984139356A5055732582 @default.
• W1984139356 hasAuthorship W1984139356A5057798874 @default.
• W1984139356 hasAuthorship W1984139356A5065917441 @default.
• W1984139356 hasAuthorship W1984139356A5076209303 @default.
• W1984139356 hasAuthorship W1984139356A5089747620 @default.
• W1984139356 hasConcept C121608353 @default.
• W1984139356 hasConcept C126322002 @default.
• W1984139356 hasConcept C143998085 @default.
• W1984139356 hasConcept C2776694085 @default.
• W1984139356 hasConcept C2776802502 @default.
• W1984139356 hasConcept C2777063308 @default.
• W1984139356 hasConcept C2777511904 @default.
• W1984139356 hasConcept C2778292576 @default.
• W1984139356 hasConcept C2778850193 @default.
• W1984139356 hasConcept C2780258809 @default.
• W1984139356 hasConcept C2780835546 @default.
• W1984139356 hasConcept C2781190966 @default.
• W1984139356 hasConcept C530470458 @default.
• W1984139356 hasConcept C71924100 @default.
• W1984139356 hasConcept C90924648 @default.
• W1984139356 hasConceptScore W1984139356C121608353 @default.
• W1984139356 hasConceptScore W1984139356C126322002 @default.
• W1984139356 hasConceptScore W1984139356C143998085 @default.
• W1984139356 hasConceptScore W1984139356C2776694085 @default.
• W1984139356 hasConceptScore W1984139356C2776802502 @default.
• W1984139356 hasConceptScore W1984139356C2777063308 @default.
• W1984139356 hasConceptScore W1984139356C2777511904 @default.
• W1984139356 hasConceptScore W1984139356C2778292576 @default.
• W1984139356 hasConceptScore W1984139356C2778850193 @default.
• W1984139356 hasConceptScore W1984139356C2780258809 @default.
• W1984139356 hasConceptScore W1984139356C2780835546 @default.
• W1984139356 hasConceptScore W1984139356C2781190966 @default.

• next